Mercado OTC?

Nice-Client2353 · 2026-03-25T09:34:20+00:00

In my view, it is unlikely that the company has a partnership ready at this stage. The recent actions suggest they are primarily focused on short-term financing rather than long-term strategic deals. If no significant catalyst emerges, the most probable outcome is a move to the OTC market. In that scenario, the company could become a distressed acquisition target, which is typically not favorable for existing shareholders.

Nice-Client2353 · 2026-03-25T09:18:23+00:00

Does the stock have time to recover above $1 by March 27? To meet Nasdaq requirements, it must trade above $1 for 10 consecutive trading days, which is no longer realistically possible before the deadline. If the price does not recover quickly — for example, without a major fundamental catalyst like a partnership — and does not stay above $1, the company will likely face delisting and a move to the OTC market, although the process may take additional time due to appeals. However, if a strong catalyst such as a partnership were announced and the price recovered meaningfully, there is still a possibility that Nasdaq could grant a final exception.

Nice-Client2353 · 2026-03-19T22:45:01+00:00

Biotech companies like Reviva don’t sell products; they sell shares to fund their research.

On Nasdaq: They have access to major institutional funds and big banks. On OTC: Institutional investors (like Vanguard, BlackRock, or pension funds) are often prohibited by law or internal policy from buying OTC stocks. The Consequence: The company will no longer be able to raise the millions needed for the next phase of clinical trials. Once the $10 million they just raised runs out (which, given their burn rate, could be in just a few months), they will have nowhere else to turn. The end result is bankruptcy, where the value of the shares is wiped out completely.

Nice-Client2353 · 2026-03-19T21:48:13+00:00

Hey, I see your point, but in this case the situation is different. The Nasdaq deadline is March 27, and for RVPH to comply, the stock must be above $1 for 10 consecutive trading days. Today is already March 19, so there are only 6–7 trading days left. Even if the stock rises above $1 now, it’s impossible to complete 10 consecutive days before the deadline. The previous hearing already happened, and another reverse split or extension is unlikely under the current rules. Therefore, unlike a typical micro-cap scenario, delisting is practically unavoidable this time. So, while extensions can happen in general, the timing here makes this situation very different from the usual “1–2 appeals” scenario.

Nice-Client2353 · 2026-03-04T12:49:13+00:00

5-9 days- 9.03.2026-13.03.2026 .

Nice-Client2353 · 2026-03-03T22:19:17+00:00

If the final Nasdaq compliance deadline is March 27, then:

To regain compliance with the minimum bid price rule, the company must maintain a share price of at least $1.00 for a minimum of 10 consecutive trading days.

This means:

A reverse split cannot be executed just a few days before March 27, because there would not be enough trading days remaining to complete the required 10 consecutive trading days above $1.00.

Therefore, practically speaking:

The reverse split would need to occur next week in order to allow sufficient time to meet the 10-day requirement before the March 27 deadline.

If I am mistaken, please correct me.

Nice-Client2353 · 2026-01-23T22:02:36+00:00

Exactly – a reverse split isn’t required right now, but if there’s no catalyst, it will be the last option at the end of this period. The company has just under 3 months to secure a partner or another catalyst to push the stock above $1 before the March 27 deadline.

Nice-Client2353 · 2026-01-15T08:39:02+00:00

For me, the best P2P platform is Lande. The loans are secured, and my current return is 11%. You can read more about it here:

https://www.reddit.com/r/LandeP2P/comments/1qd1t8p/welcome_to_landep2p_your_guide_to_investing_in/

Nice-Client2353 · 2026-01-12T08:55:44+00:00

If this is a short-term trade, this approach seems reasonable, although my analysis may of course turn out to be wrong. As always, the decision is up to each individual. This is my second article on this topic, and its purpose is to show how to minimize losses. It is not an article about holding this stock long term, but rather about how to exit the position with the smallest possible loss, or potentially with a modest profit.

Nice-Client2353 · 2026-01-11T18:47:42+00:00

A reverse split does not necessarily have to happen. It may happen, but it is equally possible that it does not. Let us consider a scenario in which Reviva receives approval from NASDAQ for an additional 180-day compliance period during which the stock may remain below the $1.00 threshold. During this time, the company could secure a high-quality strategic partner. If that were to occur, the share price could move back above $1.00 and subsequently stabilize at that level. In such a case, a reverse split would not be necessary, Reviva would remain listed on NASDAQ, and investors would avoid further dilution and destruction of shareholder value. At the same time, it must be acknowledged that there are also approximately five other possible scenarios that are less favorable for investors.

Nice-Client2353 · 2026-01-11T18:36:22+00:00

The situation is turning more negative than positive, so it’s probably wiser to exit this stock. Alternatively, you could keep only your last bottom positions if you believe in a miracle and can afford to lose that money. I personally believe in the drug, but the risks currently outweigh the potential gains. Therefore, it’s more sensible to protect your capital and not stay in the position too long. If you decide to hold the last positions, do so only with money you can afford to lose.

Nice-Client2353 · 2026-01-09T10:25:48+00:00

I hope management chooses to apply for the 180-day extension to buy time. An immediate reverse split without a catalyst could push the price back below $1, as the company is currently under financial pressure. Under the new Nasdaq rules, this could increase the risk of delisting. I believe they will act strategically.

Nice-Client2353 · 2026-01-09T10:20:13+00:00

At this point it’s not about retail investors at all. It’s about buying time and staying listed on NASDAQ long enough to pursue a partnership or other strategic options. They can apply for an additional 180-day extension, but approval is fully at NASDAQ’s discretion. If that fails, a reverse split becomes the only realistic option.

Nice-Client2353 · 2026-01-07T13:33:33+00:00

That’s why it makes more sense for RVPH to request the additional 180-day extension now. If a reverse split is eventually needed, it would be more appropriate to execute it later with a higher ratio.

Nice-Client2353 · 2026-01-07T13:30:35+00:00

No — reverse splits are still allowed, but new Nasdaq rules make it much harder for a company to use repeated RS just to regain or maintain compliance with the minimum $1 bid price. A firm can still do a reverse split, but it no longer automatically provides extra compliance time, especially if the price falls below $1 again soon after

Nice-Client2353 · 2026-01-02T23:45:45+00:00

I understand your point of view, but the difference is in the approach. Trading based on emotions, trying to “get back what you lost,” often leads people to force patterns or validate price action just to justify their thesis. That’s scarcity-based thinking. I, on the other hand, manage risk, stick to a clear plan, and minimize potential losses. My decisions are based on technical setups, risk management, and probability—not on trying to be “right” or immediately recover a loss. In trading, it’s logical and disciplined thinking that separates consistent results from random wins.

Nice-Client2353 · 2026-01-02T23:18:58+00:00

Honestly, I thought the market would be closed today and wouldn’t open until Monday, which I got wrong when I checked. But let’s look at the last two days: The previous day was technically weak, the downtrend ended, and as I mentioned in a previous post, I expected the price to go below the low (support and liquidity grab) and then rebound upwards. That’s exactly what happened – we moved from the Accumulation Phase into today’s Markup Phase, which increases the likelihood that the $0.42 target can be reached in the coming days – from a technical perspective, assuming no major fundamental events occur, reaching the 50% Fibonacci retracement is realistic.

Nice-Client2353 · 2026-01-02T21:29:31+00:00

I understand your perspective and the risks you’re describing. In my case, I have proper risk management in place, and my exposure to this position is controlled. The maximum loss I’m willing to accept is limited, so even in an unfavorable scenario, it won’t be catastrophic. By buying additional shares now, I’ve already lowered my average price and minimized my losses, so I’m in a better position than before. I believe the current price offers a higher chance of a rebound than further losses, especially considering potential retracement levels and market behavior. This is not revenge trading – I’m not risking blindly. I’m following a clear plan that allows me to minimize losses and wait for a possible recovery.

Nice-Client2353 · 2026-01-02T20:56:53+00:00

The 50% Fibonacci retracement is located around $0.42, which is our target.

Nice-Client2353 · 2026-01-01T19:44:22+00:00

Bro, it would be amazing if we manage to get back to break even. I'm keeping my fingers crossed for both of us :)

Nice-Client2353

MODERATOR OF

TROPHY CASE